Medicare beneficiaries who rely on Linzess for irritable bowel syndrome will see their monthly cost drop from $539 to $136 starting January 1, 2027. The price cut, a result of the federal government’s second round of drug price negotiations under the Inflation Reduction Act, represents a roughly 75 percent reduction for one of the most prescribed gastrointestinal drugs in the Part D program. The change affects millions of older adults managing chronic IBS and constipation, and it raises real questions about whether lower costs will drive a measurable jump in prescriptions filled.
Why a 75 percent Linzess price cut changes the math for patients
The Department of Health and Human Services selected Linzess in January 2025 as one of 15 medicines subject to government-set prices in Medicare Part D, a move detailed in an HHS announcement that outlined the second wave of drugs brought into the negotiation program. AbbVie, the drug’s manufacturer, confirmed the selection and the January 1, 2027 effective date in its annual filing with the Securities and Exchange Commission, characterizing the negotiated price as a risk factor for future revenue. The new maximum fair price of $136 per month replaces a list price of $539, slashing the out-of-pocket burden for beneficiaries who currently face high copays or coinsurance tied to that full figure.
The gap between $539 and $136 is not just an accounting change. For a Medicare enrollee on a fixed income, paying even 25 percent coinsurance on the old price meant roughly $135 a month, nearly equal to the entire negotiated price. Under the new rate, that same coinsurance structure would cost about $34. For patients who juggle multiple medications, that difference can free up cash for rent, groceries, or other prescriptions, and it can determine whether they fill their Linzess prescription every month or stretch doses to make a bottle last longer.
Clinicians who treat IBS and chronic constipation frequently see patients discontinue therapy when out-of-pocket costs spike, even if the medication is effective. With Linzess now moving into a far lower price tier, gastroenterologists and primary care physicians may feel more comfortable recommending it as a long-term option for symptom control. At the same time, some prescribers could shift patients away from cheaper but less effective regimens if they know the monthly cost of a branded drug is no longer prohibitive for those on Medicare.
A testable question follows from this shift: will the lower price produce a measurable increase in Linzess prescriptions? If Medicare beneficiaries who previously abandoned or never started therapy begin filling 30-day supplies at the reduced cost, aggregated Part D claims data for the first half of 2027 should show a noticeable uptick compared with the same period in 2026. A 30 percent increase in fills would be a strong signal that price was a primary barrier, though the actual figure will depend on formulary placement decisions by Part D plan sponsors, which have not yet been publicly detailed. Plan-level utilization management tools such as prior authorization or step therapy could blunt some of the expected growth in prescriptions even with the lower negotiated price.
CMS files and AbbVie disclosures anchor the $136 figure
The negotiated price is documented in the CMS negotiation materials for Linzess hosted by the Centers for Medicare and Medicaid Services. That dataset, available as a ZIP download on the Medicare Drug Price Negotiation Program landing page, provides the drug-by-drug breakdown for the initial price applicability year 2027, including the maximum fair price that will apply across participating Part D plans. The statutory authority for the program sits in 42 U.S.C. Section 1320f-1, which requires CMS to negotiate prices for 15 high-spend, single-source drugs in this cycle, using factors such as clinical benefit, unmet medical need, and federal research support to inform the final number.
AbbVie’s own disclosures reinforce those federal figures. In its Form 10-K for the year ended December 31, 2025, filed with the SEC, the company notes that Linzess was chosen for negotiation and that a new maximum fair price will take effect on January 1, 2027, warning investors that reduced reimbursement under Medicare could pressure revenue from the product line. The filing, available through the SEC’s EDGAR archive, lists Medicare pricing reforms among several policy changes that may affect future earnings.
Those parallel records from CMS and AbbVie give patients and clinicians an unusually clear picture of what to expect. Unlike traditional year-to-year formulary shifts, where copays can change with little advance notice, the Linzess price cut is locked in years ahead of time, allowing Medicare beneficiaries to plan for a substantially lower cost beginning in 2027. How Part D plans translate the $136 maximum fair price into specific copays will vary, but the floor for savings is already visible, and the coming years of claims data will show whether that transparency translates into better adherence and more consistent treatment for IBS and chronic constipation among older adults.
Free tool for readers: Built for Americans 55 to 80: a free, plain-English retirement check. See your Retirement Safety Score — your 0–100 number and a few steps — in about five minutes, no account needed.
